Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Capital Reinvestment Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Capital Reinvestment Ratio of 0.06x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥76.07 Million) in capital expenditures (CN¥4.69 Million). Check tangible net worth ratio of Beijing Sun Novo Pharmaceutical Research to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Sun Novo Pharmaceutical Research Co Ltd Capital Reinvestment Ratio (2017–2025)
This chart tracks Beijing Sun Novo Pharmaceutical Research Co Ltd's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Beijing Sun Novo Pharmaceutical Research.
Annual Capital Reinvestment Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Year-by-year Capital Reinvestment Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. See how much free cash does Beijing Sun Novo Pharmaceutical Research generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.46x | CN¥93.21 Million | CN¥42.43 Million | ▼ -52.2% |
| 2024 | 0.95x | CN¥32.02 Million | CN¥30.48 Million | ▲ +21.2% |
| 2023 | 0.79x | CN¥92.86 Million | CN¥72.96 Million | ▼ -21.4% |
| 2022 | 1.00x | CN¥103.96 Million | CN¥103.87 Million | ▲ +3.8% |
| 2021 | 0.96x | CN¥88.25 Million | CN¥84.96 Million | ▲ +124.3% |
| 2020 | 0.43x | CN¥62.99 Million | CN¥27.03 Million | ▼ -4.8% |
| 2019 | 0.45x | CN¥56.97 Million | CN¥25.67 Million | ▲ +21.1% |
| 2018 | 0.37x | CN¥44.11 Million | CN¥16.41 Million | ▼ -85.8% |
| 2017 | 2.62x | CN¥8.01 Million | CN¥20.96 Million | — |